Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Total Liabilities data on file, last reported at $26.3 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 282.55% year-over-year to $26.3 million in Q1 2026; TTM through Mar 2026 was $26.3 million, a 282.55% increase from a year earlier, with the FY2025 full-year figure at $26.7 million, up 264.28% from the prior year.
• Total Liabilities for Q1 2026 stood at $26.3 million, down from $26.7 million in the prior quarter.
• Over the last five years, Total Liabilities for VVOS reached as high as $26.7 million in Q4 2025 and fell as low as $6.9 million in Q1 2025.
• Historically, Total Liabilities has averaged $12.8 million across 5 years, with a median of $10.1 million in 2023.
• Across the five-year window, Total Liabilities sank 38.62% in 2025 and surged 282.55% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $8.9 million in 2022, then climbed by 15.7% to $10.3 million in 2023, then retreated by 28.97% to $7.3 million in 2024, then surged by 264.28% to $26.7 million in 2025, then retreated by 1.51% to $26.3 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $26.3 million in Q1 2026, $26.7 million in Q4 2025, and $23.1 million in Q3 2025.